Most retatrutide-vs-tirzepatide comparisons resolve to one question: which is stronger. The usual answer is retatrutide - three receptors instead of two, a higher weight-loss number, the newest thing. That framing is not wrong so much as it points at the wrong decision.
Tirzepatide is an appetite drug. It engages two receptors (GIP and GLP-1) and its whole clinical identity is durable appetite suppression with a manageable side-effect profile and years of maintenance data. Retatrutide keeps those two arms and adds a third - the glucagon receptor - which does something the other two do not: it signals the liver to burn its own fat and lifts metabolic rate, at the cost of heart-rate and skin-sensation effects tirzepatide never produces. That is a different set of jobs, not a stronger version of the same one.
The sharpest evidence that "stronger" is the wrong frame comes from the people who have run both. In community data from more than a thousand retatrutide users, the ones who switched off high-dose tirzepatide repeatedly report the same surprise: at the retatrutide dose they land on, their appetite comes back rather than dropping further. Food noise returns. A large share add cagrilintide or keep a low tirzepatide dose alongside retatrutide specifically to get the appetite suppression back.
Retatrutide can feel like less of an appetite drug than the tirzepatide it replaced, while doing more everywhere else. Hold that in mind and the comparison stops being a ranking and becomes a match between drug and goal.
At a Glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Status | Approved, broad clinical use | Investigational; Phase 2 published, Phase 3 (TRIUMPH) reporting |
| Weight-loss ceiling | About 21% at 15 mg, 72 wk | About 24% at 12 mg, 48 wk (Phase 2) |
| Where the curve flattens | Above 10 mg | Above 8 mg |
| Liver fat | Falls with weight loss (about 47-50% by MRI) | Direct hepatic effect: 43% at 1 mg, 81% at 8 mg by 24 wk |
| Appetite feel | Strong, durable, flat | Often lighter per dose; food noise can return on a switch |
| Heart rate | Small (about +2-3 bpm at steady state) | Dose-scaling glucagon effect (+9 bpm peak at 12 mg, fades by half) |
| Distinct side effect | GI during titration | Skin burning/tingling at high dose; fatigue; cold hands |
| Best fit | Appetite-driven loss, stable maintenance | Plateau, liver fat, visceral fat, metabolic throughput |
What Separates Them
Both drugs are built from the same idea: engage the gut-hormone receptors that control appetite and blood sugar, but tune each receptor to a deliberate strength rather than copying the natural hormone. Where they differ is which receptors, and how hard.
Two numbers matter before the receptor table, because they are the ones most often misread. First, "potency" and "efficacy" are different things. Potency is how much drug it takes to switch a receptor on; efficacy is how loud the signal gets once it is on. Retatrutide and tirzepatide are both full agonists at every receptor they hit - the signal reaches full strength (efficacy near 100% of the natural hormone). They differ on potency, which is why the ratios below read as "×native" rather than as fractions of the effect.
| Receptor | What its signal does | Tirzepatide potency | Retatrutide potency |
|---|---|---|---|
| GIP | Meal-time insulin efficiency; fat-cell metabolism; buffers nausea | About native | About 8.9× native |
| GLP-1 | Appetite suppression; slowed stomach emptying; satiety | About 0.05× native | About 0.4× native |
| Glucagon | Liver burns its own fat; raised metabolic rate; heart-rate effects | None | About 0.3× native |
Three things fall out of this table, and each one drives a downstream decision.
The GIP arm is where retatrutide front-loads. Its GIP potency is roughly nine times the natural hormone's and far above tirzepatide's, so retatrutide reaches heavy GIP engagement at low doses. Most of that GIP benefit is online by 1-4 mg; climbing higher mostly adds appetite pressure and glucagon signal, not more GIP. The GIP arm also does quiet tolerability work - it calms the nausea circuit in the brainstem, which is part of why both drugs tolerate higher appetite pressure than a pure GLP-1 drug like semaglutide (brainstem GIP-receptor buffering¹).
At the GLP-1 receptor, the two behave differently in a way potency alone hides. Retatrutide is the more potent of the pair here (its GLP-1 potency is roughly eight times tirzepatide's), so per dose it engages more receptor. Tirzepatide gets more durable signal out of each receptor it does engage.
The reason is a second signal the receptor can send, one that pulls it off the cell surface and quiets it over time. Tirzepatide barely triggers that wind-down arm (it is the most one-sided of the class), so its GLP-1 receptors keep signaling steadily under weekly dosing. Retatrutide triggers it more, about 40% of the natural hormone's level, part-way toward how a natural GLP-1 drug behaves (biased-agonism at the GLP-1 receptor²).
The practical translation: tirzepatide's appetite effect is built to hold flat and durable; retatrutide's is more dose-dependent and, at the doses people switch into, often lighter.
Tirzepatide has no glucagon arm. Retatrutide's is the whole difference. Glucagon receptor engagement is what gives retatrutide a direct liver-fat signal, a lift in metabolic rate, and the heart-rate, cold-extremity, and skin-sensation effects tirzepatide does not carry. It also does not switch on evenly across the dose range: the hepatic (liver) effects appear at low doses where the heart is barely engaged, and the peripheral effects (heart rate, cold hands) come online from about 4 mg upward. One molecule with a different pharmacology at the bottom and top of its own dose range.
Switching From Tirzepatide
The most common real-world scenario is a person on tirzepatide 10-15 mg whose weight loss has stalled, wondering whether retatrutide is the next move. The community data on people who made that exact switch is the most useful evidence available, and it corrects two assumptions at once.
CHART — Tirzepatide-to-retatrutide dose landing. A flow or slope chart mapping the tirzepatide dose people left (2.5, 5, 7.5, 10, 12.5, 15 mg) to the retatrutide dose they restarted at, from the switcher records. The dominant pattern: people leaving 10-15 mg tirzepatide restart retatrutide at 0.5-2 mg, not at a "converted" milligram. A minority who matched their old milligram (started reta at 6-8 mg) cluster in the fatigue/whiplash reports. Source: reddit switcher dataset, n=181 tirz-connected retatrutide users.
Assumption one: retatrutide is a stronger tirzepatide, so a plateaued 15 mg user needs a high retatrutide dose. The switcher reports say the opposite. Coming off 10-15 mg tirzepatide, the people who do well restart retatrutide low - commonly 1-2 mg - and treat it as a new drug.
The ones who carry their milligram across, or jump straight to 6-8 mg to "match" the tirzepatide they left, describe the switch as brutal: crushing fatigue, nausea, appetite collapse, puffiness, and resting-heart-rate spikes. One described first hitting 12 mg after a slow climb as getting hit "like a ton of bricks."
That is not how retatrutide feels - it is what landing the entire glucagon arm at once feels like. Months of tirzepatide leave the appetite receptors used to the signal, but the heart, GI, and thermoregulatory systems have never seen the glucagon arm and have to adapt to it from zero.
Assumption two: appetite suppression will get stronger on the switch. For a large share of switchers, it gets weaker. This is the finding that most contradicts the "stronger drug" story, and it recurs across independent reports: after switching, food noise comes back, hunger returns in the first weeks, some regain a few pounds before settling.
One switcher moving from 10 mg tirzepatide to 4 mg retatrutide put it plainly - they had been maintaining, started losing again on retatrutide, but had not realized how much the tirzepatide had been doing until it was gone. Another, weeks into the switch, described a "mild reduction in food interest, but not the same as tirz."
The mechanism is exactly the receptor difference from the last section. At the modest doses people switch into, retatrutide's GLP-1 engagement is lower than a high tirzepatide dose delivers, and it lacks tirzepatide's durable, one-sided GLP-1 signaling - so the appetite lever is genuinely lighter. Retatrutide is making up the weight-loss difference through the glucagon and GIP arms (liver, metabolic rate, fat-cell handling), not through more appetite suppression.
Which is why the switcher population does something telling: they patch the appetite gap. In the dataset, close to half of the tirzepatide switchers kept a low tirzepatide dose or restacked it alongside retatrutide, and a smaller group added cagrilintide (an amylin-based appetite agent) specifically for food-noise control. Roughly two in five referenced splitting or spacing their retatrutide dose, twice-weekly rather than once, to work with its roughly six-day half-life and smooth the peaks.
These are posting-sample patterns, not clinical incidence rates, but the direction is consistent, and it tells you what the switch is about: retatrutide is being run for its metabolic and hepatic arm, with the appetite suppression topped up from elsewhere.
One caution travels with this. Some switchers attribute muscle loss to retatrutide's lighter appetite control (the theory being that erratic eating without strong appetite suppression costs lean mass). The trial evidence does not support a retatrutide-specific lean-mass penalty - the direct body-composition data (DXA) shows a fat-to-lean loss ratio comparable to the rest of the class. The appetite difference on a switch is real and reported; the muscle-loss claim attached to it is a user theory, not a finding.
A starting frame for the switch
There is no clean conversion. The values below are a tolerance-and-adaptation window, not a milligram equivalence.
| Current tirzepatide dose | Retatrutide entry | Possible later target if tolerated |
|---|---|---|
| 2.5-5 mg | 0.5-1 mg | 2-4 mg |
| 7.5-10 mg | 1-2 mg | 4-8 mg |
| 12.5-15 mg | 1-2 mg | 6-12 mg |
The entry dose is a test of how the glucagon arm lands, not a dose meant to reproduce the old weight-loss rate immediately. Trial and community practice both point to a four-week floor between steps, held longer if nausea, reflux, constipation, fatigue, chills, insomnia, skin sensitivity, or an elevated resting heart rate is still active - each of those marks a body that has not finished adapting to the current dose.
Where Retatrutide Wins: Liver Fat
If the goal is weight loss, the two drugs are closer than the ceiling numbers suggest. If the goal is liver fat, they are not close, and the reason is the glucagon arm doing direct work rather than waiting on weight loss.
In a study of 98 non-diabetic adults with obesity and at least 10% baseline liver fat, measured directly by MRI, retatrutide reduced liver fat at every dose, and most of the effect arrived by the halfway point of the trial³:
CHART — Retatrutide liver-fat reduction by dose. A grouped bar or dose-response chart, liver-fat reduction at 24 and 48 weeks against dose. Key points: placebo about +0.3% (24 wk) / -4.6% (48 wk); 1 mg -42.9% / -51.3%; 4 mg -57.0% / -59.0%; 8 mg -81.4% / -81.7%; 12 mg -82.4% / -86.0%. The story the chart should show: the 8 mg and 12 mg bars are nearly identical, and each dose's 24-week and 48-week bars are nearly identical - the hepatic effect saturates by 8 mg and by 24 weeks. Source: Sanyal 2024, Nat Med (MASLD substudy).
Two readings matter. The hepatic effect saturates at 8 mg - the jump to 12 mg buys about one percentage point more liver-fat reduction in exchange for the full glucagon-class side-effect load, which is a poor trade for a liver-fat-primary goal. And the effect is mostly a 24-week story: at 8 mg, the liver-fat reduction at 24 weeks (81.4%) is indistinguishable from 48 weeks (81.7%), while weight loss keeps going. The liver reaches its floor early.
Even 1 mg is a real hepatic dose, not a starter. At one-eighth of the top dose it cut liver fat by 43% and got 27% of participants to a normal liver-fat level. The blood marker for the liver actively burning fat (beta-hydroxybutyrate) rose 93% at 4 mg and 181% at 12 mg in the same trial - direct evidence the glucagon arm is doing hepatic work, not just riding weight loss (ketone/fatty-acid-oxidation signal³).
Tirzepatide improves liver fat too, but mostly as a consequence of weight loss and better insulin handling, which is a slower and shallower route to the same compartment.
This reshapes who retatrutide is for. Someone with a fatty-liver or visceral-fat problem at a lower BMI - the pattern common in South Asian metabolic risk and in family histories of type 2 diabetes, where fat accumulates in the liver and belly before the scale looks alarming - has a mechanism-matched reason to choose retatrutide, and to choose a lower dose than a weight-loss goal would call for. The question shifts from how much weight to lose to how much liver fat to mobilize, and the dose that answers it is lower.
The Side Effects That Differ
At matched weight loss, the two drugs feel different, because different pharmacology is producing the same scale number. The GI burden (nausea, slowed gut, constipation) is common to both and tracks titration speed on either. The differences that matter for choosing are the ones retatrutide's glucagon arm adds.
Heart rate is the clearest divergence. Tirzepatide's heart-rate effect is small and belongs to the incretin class - a steady-state mean rise of about +0.6 to +2.6 bpm across 5-15 mg by week 72, with a larger, temporary bump during escalation.
Retatrutide's is a dose-scaling glucagon effect and it is bigger: by 24-hour monitoring, about +0.7 bpm at 1 mg, +2 to +4 bpm at 4 mg, and up to +9.2 bpm at 12 mg, peaking in the first few months and fading by roughly half by week 48 as the body adapts⁴. A person who does not lose much weight sees less of the fade.
This is the single most important reason retatrutide's dose is not a milligram conversion from tirzepatide - the heart-rate arm has to be titrated into.
CHART — Heart rate by drug and dose. Two lines: tirzepatide steady-state pulse change by dose (about +0.6 / +2.3 / +2.6 bpm at 5 / 10 / 15 mg) and retatrutide 24-hour ABPM change by dose (about +0.7 / +2-4 / +5.7-6 / +9.2 bpm at 1 / 4 / 8 / 12 mg). The chart should make the shape difference obvious: tirzepatide stays flat and low; retatrutide climbs with dose. A note that retatrutide's peak attenuates about half by week 48. Sources: SURMOUNT-1 Table S7 (tirz); Jastreboff 2023 Supp Table S8 (reta).
Skin burning and tingling is a retatrutide high-dose signal. Burning, tingling, or skin that reads light touch as painful (dysesthesia) shows up at retatrutide's top doses - about 12% at 9-12 mg in the main obesity trial and as high as 21% at 12 mg in a knee-osteoarthritis trial, against under 1% on placebo⁵. It is dose-dependent, reversible, and rarely a reason to stop, but people arriving from tirzepatide do not expect it.
This is a GLP-1-receptor-class effect, not a glucagon one - semaglutide, which has no glucagon or GIP arm, carries the strongest version of it - so it tracks GLP-1 engagement, and tirzepatide's lower rate reflects its lighter GLP-1 receptor engagement, not protection from its GIP arm.
Fatigue and cold hands are the glucagon-arm felt costs. In the switcher reports, fatigue is a more common complaint than in tirzepatide's GI-dominated profile - part of the "exposure whiplash" when the glucagon arm lands too fast, and part of running a real caloric deficit with a lighter appetite brake. Cold extremities follow the same dose-dependent pattern as the heart-rate rise. Both ease on a dose drop; both are the same glucagon mechanism that does the wanted hepatic work at low dose, scaled to peripheral tissue at high dose.
The energy or "running warm" signal is retatrutide-only, and it is smaller than sometimes claimed. The glucagon arm's lift in metabolic rate is real in the liver and ketone data, but a clean whole-body energy-expenditure number has not been published, and class-comparator data suggests a modest 3-7% rise at high dose at most. Tirzepatide has no glucagon arm and no equivalent signal. This is a genuine point of difference, not a reason to expect a thermogenic transformation.
Which One, for Which Goal
Weight-loss outcomes line up across a handful of dose pairs, and both drugs saturate - most of the effect is captured below the top dose. The pairing below is for weight loss only; it does not hold for liver fat, and the side-effect trade differs at every rung.
| Goal | Tirzepatide | Retatrutide | Expected weight loss |
|---|---|---|---|
| Steady 10-13% loss, minimal disruption | 4-5 mg | 2 mg | 12-14% either way |
| Serious 20% loss | 10 mg | 5 mg | About 20% either way |
| Maximum loss, willing to pay in side effects | 15 mg | 8-12 mg | Tirz about 21%; reta 24-28% |
| Lean or metabolic-optimization, hepatic goal | 2.5 mg (closest track) | 0.3-1 mg | Reta 1 mg: about 9%; tirz: low-dose maintenance |
Two plain readings. Retatrutide reaches a matched weight-loss outcome from a smaller milligram number through most of the range - its 5 mg lands near tirzepatide's 10 mg - though that says nothing about tolerability, and the gap compresses at the top. And the two middle rungs are genuinely a coin toss on weight: either drug delivers 10-20% with a different side-effect surface, so the choice there is about which trade suits the person, not which drug is stronger.
Retatrutide's real edges are at the ends and off the weight axis: the higher ceiling for a true ceiling-seeker, the microdose story for a lean or hepatic goal, and liver fat, where it is not a close comparison. Tirzepatide's edges are the ones that matter for most people most of the time: a known dose ladder, the deepest maintenance and safety record in the class, a directly measured body-composition profile that holds across subgroups, and an appetite effect that stays flat and durable without a second agent to prop it up.
Real-world prescribing already reflects this. Across five recent cohorts of more than 40,000 tirzepatide users, most persistent users settle at sub-10 mg dosing, with 5 mg the common maintenance dose and 11-13% measured six-month weight loss in non-diabetic users⁶. The ladder gets used as a ladder, not a race to 15 mg.
FAQ
I am on 15 mg tirzepatide and stalled. Would retatrutide help?
Possibly, if it is a true plateau and not a protein, sleep, training, alcohol, or dose-timing problem. Retatrutide at 8-12 mg can move past tirzepatide's ceiling and does far more for liver fat. The switch is not free: expect the appetite brake to feel lighter at first (food noise can return), a real heart-rate arm to titrate into, possible fatigue and cold hands, and skin tingling at the top doses. Restart low - 1-2 mg, not a matched milligram - and treat it as a new drug.
Why did my appetite come back after switching to retatrutide?
Because at the dose most people switch into, retatrutide engages the appetite receptor less than a high tirzepatide dose did, and it lacks tirzepatide's durable, one-sided GLP-1 signaling. Retatrutide makes up the weight-loss difference through its liver and metabolic-rate arm, not through more appetite suppression. Many switchers keep a low tirzepatide dose or add cagrilintide to get the food-noise control back while retatrutide does the metabolic work.
My heart races and my fingers feel cold on retatrutide. What is that?
Both are glucagon-arm effects and both scale with dose. Heart-rate elevation peaks in the first few months and fades by roughly half by around week 36-48; cold extremities follow the same curve. A drop to 4 mg reduces both, and 2 mg largely clears them. Either symptom turning severe, or arriving with chest pain, shortness of breath, or dizziness, moves it out of routine titration and into a clinical question.
I have elevated liver fat on imaging. Which drug and dose?
Retatrutide is the more direct tool - 1-8 mg depending on severity and tolerance. Even 1 mg cut liver fat 43% at 24 weeks in the MRI substudy; 8 mg is the effective ceiling, since 12 mg adds about one percentage point for a full side-effect load. Tirzepatide improves liver fat too, but mostly through weight loss, which is a slower and shallower route to the same compartment.
Can I microdose either for metabolic health?
Retatrutide 0.3-1 mg is the more distinctive microdose - meaningful liver and metabolic work at low appetite pressure, best suited to lean, recomp, or hepatic goals. Retatrutide 1 mg produced about 9% weight loss and 43% liver-fat reduction in trials. Tirzepatide's low-dose story is maintenance-oriented (2.5 mg is a real lower-dose track), and it does not reproduce retatrutide's liver arm.
Is retatrutide "the strongest," like Reddit says?
At the top of its curve, it produces the largest weight loss demonstrated in the class, so directionally yes. But "strongest" hides the structure that matters: retatrutide's advantage is concentrated at the ceiling, at microdose, and at liver fat. In the middle of the range, either drug delivers similar weight loss with a different side-effect trade, and on a switch, retatrutide's appetite effect can feel weaker, not stronger. It is a different tool, sharper for specific jobs.
Related Reading
- Tirzepatide Guide: Dosing, Results, and Side Effects - the full tirzepatide dose-response and the tirzepatide-vs-semaglutide split.
- Retatrutide: A Coherent Multi-Receptor Signal - the extended retatrutide pharmacology and hepatic-fat evidence.
- Retatrutide Side Effects - the full adverse-event surface: dose-response, dysesthesia, titration speed, phenotype.
- GLP-1 Lean Mass Preservation - body composition across semaglutide, tirzepatide, and retatrutide.
- GLP-1 Hub - the broader GLP-1 family.
For dosing: tirzepatide dosage calculator and retatrutide dosage calculator. For side-by-side exploration: GLP-1 comparison tool.
References
¹ GIP-receptor brainstem buffering of nausea - GIP-receptor agonism quiets the emetic circuit in the hindbrain (area postrema and NTS), a mechanism proposed to underlie the tolerability of GIP/GLP-1 co-agonists. Borner T, De Jonghe BC, Hayes MR (2024) Am J Physiol Endocrinol Metab 326:E528-E536.
² Biased agonism at the GLP-1 receptor - both drugs are full agonists on the productive (cAMP) signal but recruit the receptor's wind-down arm (beta-arrestin) to different degrees: tirzepatide minimally (not fittable / under about 15-25% of native across assays), retatrutide about 40% of native. Coskun T et al. (2022) Cell Metab 34:1234-1247 (Table S2); Willard FS et al. (2020) JCI Insight 5:e140532. Independent confirmation of the cAMP-bias direction: Oostdyk L et al. (2024) Eurofins Discovery functional profiling (operational-model bias).
³ Retatrutide MASLD substudy - 98 non-diabetic adults with obesity and at least 10% baseline liver fat, MRI-PDFF, 48 weeks. 1 mg: 43% liver-fat reduction at 24 wk; 8 mg: 81%; beta-hydroxybutyrate +181% at 12 mg. Sanyal AJ et al. (2024) Nat Med 30:2037-2048 [DOI 10.1038/s41591-024-03018-2].
⁴ Retatrutide heart-rate dynamics - Jastreboff 2023 Supp Table S8 (24-hour ABPM at week 24, non-diabetic obesity): +0.7 bpm at 1 mg, +2.2 to +4.2 at 4 mg, +5.7 to +6.0 at 8 mg, +9.2 (95% CI 7.4 to 11.1) at 12 mg; roughly half the peak attenuated by week 48. Tirzepatide steady-state pulse: SURMOUNT-1 Table S7, +0.6 / +2.3 / +2.6 bpm at 5 / 10 / 15 mg, week 72. Jastreboff AM et al. (2023) N Engl J Med 389:514-526; Jastreboff AM et al. (2022) N Engl J Med 387:205-216.
⁵ Retatrutide dysesthesia - 12.3-12.5% at 9-12 mg in the main obesity readout and 20.9% at 12 mg in a knee-osteoarthritis trial, vs under 1% placebo; dose-dependent, reversible. It is a GLP-1-receptor-class effect (semaglutide carries the strongest pharmacovigilance signal despite having no GIP or glucagon arm), not glucagon-driven. Jastreboff AM et al. (2023) N Engl J Med 389:514-526; Laroche ML et al. (2026) Eur J Clin Pharmacol 82:154.
⁶ Real-world tirzepatide dosing - five datasets totaling more than 40,000 users showing sub-10 mg maintenance as the dominant pattern: Mody 2025 (n=15,667), Hankosky 2025 (n=4,177 and n=20,998), Le Roux 2026 (n=2,396), Duncan 2026 (n=1,166).
⁷ Receptor potency ratios - GIP, GLP-1, and glucagon cAMP potencies measured in low-receptor-density assays. Retatrutide values from Coskun 2022; tirzepatide from Willard 2020 (Coskun used Willard's method), with a small cross-lab offset, so the figures are ratios rather than exact multiples. All three retatrutide receptor engagements are full agonism by efficacy (Emax about 104-115% of native); the ratios are potency, not efficacy. Coskun T et al. (2022) Cell Metab 34:1234-1247; Willard FS et al. (2020) JCI Insight 5:e140532.
⁸ Switcher patterns - community dataset of 1,839 retatrutide users (Reddit RWE, v2.0), of whom 181 came to retatrutide from tirzepatide. Patterns cited (low restart dose off high tirzepatide; appetite return; near half keeping or restacking low-dose tirzepatide; roughly two in five splitting or spacing doses around retatrutide's roughly six-day half-life; about 14% adding cagrilintide) are prevalence-among-posters, not clinical incidence.
⁹ Body composition - retatrutide's fat-to-lean loss ratio is comparable to the GLP-1 class by DXA; the "retatrutide costs more muscle" claim in switch reports is a user theory the trial data does not support. Tirzepatide DXA: 75:25 fat-to-lean, holding across sex, age, and weight-loss subgroups; Look M et al. (2025) Diabetes Obes Metab 27:2720.
Retatrutide weight-loss anchors: Phase 2 obesity 24.2% at 12 mg / 48 wk (Jastreboff AM et al. 2023, N Engl J Med 389:514-526, NCT04881760); the Phase 3 TRIUMPH program is reporting and topline figures run higher but are not yet at full-publication detail. Tirzepatide: 20.9-21% at 15 mg / 72 wk (SURMOUNT-1). A direct head-to-head (NCT06662383) and a retatrutide cardiovascular-outcomes trial (NCT06383390) are registered; until they report, every cross-drug magnitude claim here is an indirect comparison across different trials and populations.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.